Table 1.
Rate of abnormal liver function tests in patients with COVID-19
| Study | Sample size, n | Pre-existing chronic liver disease/liver conditions, % | Abnormal liver functions |
|---|---|---|---|
| Huang et al. [17] | 41 | 2.4 | Elevation of AST: 36.6% |
| Guan et al. [2] | 1,099 | 2.1 | Elevation of AST: 22.2%; ALT: 21.3%; total bilirubin: 10.5% |
| Cai et al. [53] | 298 | 2.7 | Elevation of AST: 8.7%; ALT: 8.7%; total bilirubin: 3.1% |
| Fan et al. [54] | 148 | 5.4 | Elevation of AST: 21.6%; ALT: 18.2%; total bilirubin: 6.1% |
| Wang et al. [19] | 138 | 2.9 | N/A |
| Shi et al. [18] | 81 | 8.6 | Elevation of AST: 53.1% |
| Xu et al. [20] | 62 | 11.3 | Elevation of AST: 16.1% |
| Yang et al. [4] | 52 | N/A | 28.8%a |
| Zhang et al. [23] | 56 | 3.6 | 28.6%a |
ALT, alanine aminotransferase; AST, aspartate aminotransferase; N/A, not available.
a
Specific liver function parameters were not reported.